Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
Inozyme Pharma Inc (NASDAQ: INZY) closed the day trading at $4.51 down -1.53% from the previous closing price of $4.58. In other words, the price has decreased by -$1.53 from its previous closing price. On the day, 0.59 million shares were traded. INZY stock price reached its highest trading level at $4.63 during the session, while it also had its lowest trading level at $4.38.
Ratios:
For a better understanding of INZY, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 13.36 and its Current Ratio is at 13.36. In the meantime, Its Debt-to-Equity ratio is 0.33 whereas as Long-Term Debt/Eq ratio is at 0.33.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Jefferies on March 23, 2023, Upgraded its rating to Buy and sets its target price to $6 from $4.50 previously.
On May 26, 2022, Jefferies started tracking the stock assigning a Hold rating and target price of $5.
On February 07, 2022, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $33.H.C. Wainwright initiated its Buy rating on February 07, 2022, with a $33 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 02 ’24 when Treco Douglas A sold 7,523 shares for $6.94 per share. The transaction valued at 52,210 led to the insider holds 20,665 shares of the business.
Hopfner Robert Lorne bought 833,333 shares of INZY for $3,999,998 on Aug 01 ’23. The Director now owns 2,923,110 shares after completing the transaction at $4.80 per share. On Aug 01 ’23, another insider, Pivotal bioVenture Partners Fu, who serves as the Director of the company, bought 833,333 shares for $4.80 each. As a result, the insider paid 3,999,998 and bolstered with 2,923,110 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, INZY now has a Market Capitalization of 278591744 and an Enterprise Value of 136594624.
Stock Price History:
Over the past 52 weeks, INZY has reached a high of $7.80, while it has fallen to a 52-week low of $2.69. The 50-Day Moving Average of the stock is -24.17%, while the 200-Day Moving Average is calculated to be -5.41%.
Shares Statistics:
Over the past 3-months, INZY traded about 661.03K shares per day on average, while over the past 10 days, INZY traded about 942920 shares per day. A total of 61.77M shares are outstanding, with a floating share count of 41.14M. Insiders hold about 33.41% of the company’s shares, while institutions hold 58.15% stake in the company. Shares short for INZY as of 1711584000 were 2582921 with a Short Ratio of 3.91, compared to 1709164800 on 2319477. Therefore, it implies a Short% of Shares Outstanding of 2582921 and a Short% of Float of 4.21.
Earnings Estimates
The stock of Inozyme Pharma Inc (INZY) is currently drawing attention from Incyte Corporation analysts actively involved in the ongoing evaluation and rating process.
